Results 61 to 70 of about 81,723 (303)
Advanced Healthcare Materials, EarlyView.A long‐lived, five‐cell‐type human neurovascular (PENTA) model recreates vascular disorganization and incomplete repair after traumatic brain injury (TBI). By integrating endothelial, glial, neuronal, and immune components within a 3D scaffold, the platform enables time‐resolved analysis of neurovascular remodeling and provides a human‐relevant system ...
Daniel S. Hinrichsen +6 more
wiley +1 more source
Rapid resolution of non-segmental vitiligo in a patient treated with abrocitinib: A case report
SAGE Open Medical Case ReportsVitiligo is a common, autoimmune, depigmenting disorder of the skin. Janus Kinase inhibitors have emerged as promising topical and oral therapeutic options for vitiligo.
Seyyon Satkunanathan +3 more
doaj +1 more source
c-Src binds to the cancer drug Ruxolitinib with an active conformation. [PDF]
PLoS ONE, 2014 The cancer drug Ruxolitinib is a potent janus kinase inhibitor approved for the treatment of the myeloproliferative neoplasms. In addition, Ruxolitinib has weak inhibitory activity against a panel of other kinases, including Src kinase.
Yankun Duan +3 more
doaj +1 more source
Role of mTOR signaling in tumor microenvironment. An overview [PDF]
, 2018 The mammalian target of rapamycin (mTOR) pathway regulates major processes by integrating a variety of exogenous cues, including diverse environmental inputs in the tumor microenvironment (TME).
Bazzichetto, Chiara +8 more
core +2 more sources
Janus kinase inhibitors - holistically seeing two faces
Australian Prescriber, 2015 Editor, - I was interested to read the recent article on Janus kinase inhibitors by Paul Kubler (Aust Prescr 2014;37:154-7). In addition to being pro-cancer, the Janus kinase-Signal Transducer and Activation of Transcription (JAK-STAT) pathway is part of a central physiological pro-survival mechanism.1 Thus pharmacological targeting of this signalling ...
John A Loudon, Paul Kubler
openaire +2 more sources
Nanotherapies for Atherosclerosis: Targeting, Catalysis, and Energy Transduction
Advanced Healthcare Materials, EarlyView.Atherosclerosis management is hindered by poor drug targeting and plaque heterogeneity. Nanotechnology overcomes these barriers via three core strategies: (1) target‐engineered nanocarriers that achieve lesion‐specific precision via ligand modification, biomimetic camouflage, stimuli‐responsive release, and self‐propelling nanomotors; (2) catalytic ...
Yuqi Yang +4 more
wiley +1 more source
Role of the bone morphogenic protein pathway in developmental haemopoiesis and leukaemogenesis [PDF]
, 2016 Myeloid leukaemias share the common characteristics of being stem cell-derived clonal diseases, characterised by excessive proliferation of one or more myeloid lineage.
Toofan, Parto, Wheadon, Helen
core +1 more source
Bottom‐Up Programming of Cell States in Cancer Organoids with Defined Synthetic Adhesion Cues
Advanced Materials, EarlyView.A bottom‐up biomaterial platform is developed to program transcriptomic states in pancreatic cancer organoids by tuning adhesion cues within synthetic matrices. By combining a Design of Experiments framework with multiobjective optimization, matrix compositions are identified that enrich specific cellular programs like EMT.
Ali Nadernezhad +6 more
wiley +1 more source
Negative patch test findings after initiation of upadacitinib: A case report
SAGE Open Medical Case ReportsUpadacitinib is a systemic Janus kinase inhibitor currently approved for the treatment of atopic dermatitis. Many patients with atopic dermatitis have a concomitant diagnosis of allergic contact dermatitis.
Meghan L McPhie +2 more
doaj +1 more source
Tumor Biology, 2017 Chronic myeloid leukemia is characterized by the presence of the reciprocal translocation t(9;22) and the BCR/ABL oncogene. The BCR/ABL oncogene activates multiple signaling pathways and involves the dysregulation of oncogenes during the progression of ...
Jia-Hua Zhang +4 more
doaj +1 more source